David Roblin, CEO of Relation Therapeutics, said: "This financing is a significant milestone for Relation Therapeutics and underscores the confidence our investors have in our innovative approach to ...
Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...
In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback